Acknowledgement and Consent for Disclosure of Potential Conflict(s) of Interest and Waiver under 18 U.S.C. § 208(b)(3)

	C . CC.		-
N/1 2 11A	Griffin,	N/I	11
waiic	OHIIII.	IVI.	. v.

Committees: Joint Nonprescription Drugs Advisory Committee and Endocrinologic

and Metabolic Drugs Advisory Committee Meeting

Meeting Dates: January 23, 2006

I acknowledge that contingent upon public disclosure of the financial interest listed below, related to agenda item new drug application (NDA) 21-887, proposing over-the-counter (OTC) use of Orlistat (tetrahydrolipstatin) 60 milligram (mg) capsules, sponsored by GlaxoSmithKline Consumer Healthcare, L.P., an associate of GlaxoSmithKline PLC, to promote weight loss in overweight adults when used along with a reduced calorie and low fat diet, I am eligible to receive a waiver under 18 U.S.C. § 208(b)(3).

Type of Interest	Nature	Magnitude		
Consulting on unrelated matter.	Competitor	From \$10,001 to \$50,000 a year		
I hereby request that FDA make this information publicly available on my behalf. I understand that without public disclosure of this interest the waiver is not valid.				
/s/	12/2	3/05		
Signature of SGE	Date			